PPAR-γ Impairment Alters Peroxisome Functionality in Primary Astrocyte Cell Cultures
Figure 7
(a) PMP70, (b) ACOX1, and (c) NDUFS3 expression: effect of G3335. Astrocytes (5 105 cells/well) were treated with the reversible PPAR antagonist G3335 (30 μM) for 2 days or 5 days, in the absence or presence of the PPAR agonist rosiglitazone (100 μM). Values are expressed as the mean ± S.E.M. percent of control of three experiments. Control condition was arbitrarily set as 100%.
